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The increasing awareness of biological information coding by glycans, the third alphabet of life,
1
 has 
stimulated efforts to prepare bioactive oligosaccharides. A common route toward this aim starts with 
thioglycosides.
2
 Inspired by their versatility as glycosyl donors, the applicability of a sulfur atom at 
the anomeric center had been extended to disulfides.
3
 They are also readily produced by disulfide 
exchange in dynamic combinatorial libraries
4
 and constitute attractive tools for studying structural 
properties of a glycosidic linkage in a three-bond system.
5
 Along these lines, selenoglycosides and 
respective selenylsulfides, too, proved their merits for synthetic purposes.
6
 Beyond preparative 
aspects, the resistance to hydrolysis gives reason to examine their capacity for protein-carbohydrate 
interactions, to define consequences of geometric and electronic changes by substituting oxygen with 
S/Se.  
The symmetric thiodigalactoside (TDG) has gained prominence as potent inhibitor of lectin-
dependent haemagglutination in the pioneering studies on detecting and purifying galectins
7
, a 
family of adhesion/growth-regulatory lectins.
8
 Interestingly, the corresponding disulfide was much 
less reactive with galectins but maintained its blocking capacity to a highly toxic plant lectin, i.e. the 
mistletoe lectin (Viscum album agglutinin, VAA) akin to the biohazard ricin.
9
 Because computational 
analysis of flexibility and energy grading of the conformational space of thio- and seleno derivatives 
of high-affinity lectin ligands, i.e. histo-blood group ABH antigens, inferred an increase of dynamics 
and access to new secondary conformations,
10
 the following questions on S,Se-glycosides needed to 
be answered: 
Will inhibitory potency of disulfides be increased by glycocluster formation? 
Will the Se-derivatives of the symmetric digalactoside be lectin ligands, considering the alterations 
between C-Se/C-S/C-O bond angles (95°/95°/115°) and length (1.9 Å/1.8 Å/1.4 Å)? 
To address the first issue a benzene-based core was used as scaffold for presenting one, two and 
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Scheme 1. Structures of the benzene-based mono-, di- and trivalent disulfides presenting  
D-galactose. 
 
These mono-, di- and trivalent compounds were comparatively tested under identical conditions as 
inhibitors of lectin binding (the lectins were prepared and controlled for activity as described in 
detail elsewhere
9a, 12
). In the first setting, a neoglycoprotein (a carrier protein devoid of lectin 
reactivity, i.e. bovine serum albumin, presenting 28-30 chemically conjugated Lac derivatives
13
) was 
adsorbed to the surface of microtiter plate wells to establish a lectin-reactive matrix with structurally 
unambiguously defined sugar part. Binding was saturable and completely dependent on the cognate 
carbohydrate (not shown). Titrations with increasing additions of the sugar compounds 1, 2 & 3 to 
the lectin-containing solutions resulted in reduction of the signal recorded by photometry and thus in 
the determination of the inhibitory concentration (IC) that reduced extent of binding to 50% (IC50). 
As compiled in Table 1, increase in relative inhibitory potency with valency was pronounced for the 
4 
 
toxin. Inhibitory capacity below the 5 mM threshold was seen for Gal-3, -4 and -9N when exposed to 
the trivalent compound. Obviously, the individual sugar units of the trivalent glycocluster maintained 
activity, as had also been reported for the tetrameric concanavalin A based on calorimetric 
titrations.
14
 Increasing the biorelevance of the assay, the three synthetic compounds were next 
included as inhibitors in cell assays. Here, extent of lectin binding was quantitated by 




The symmetric dithiodigalactoside (DTDG) and the monovalent compound 1 were slightly more 
active than free Gal, bivalent compound 2 being comparatively strong as in the solid-phase assay 
(Fig. 1A). This synthetic compound also surpassed the activity of free Lac, but was less potent than 
trivalent compound  3 (Fig. 1B). Tested at 2 mM, progressive decreases in percentage of positive 
cells were observed for galectins with increases in valency, e.g. for Gal-3 and colon cancer (SW480) 
cells graded reductions from 84% (100% value) to 75% (cpd 1), 68% (cpd 2) and 61% (cpd 3) were 
determined, 52% measured for Lac as reference. Thus, clustered disulfides are effective to block the 
toxin, with comparatively rather small reactivity to cellular galectins, although a relative increase of 
inhibitor capacity with valency was noted. Because 1,3,5-triiodobenzene or tris(alkynyloxy)benzene 
as core for presentation of Lac had yielded cluster effects for Gal-3,
15
 the disulfide helps to 
downregulate the ligand reactivity. 
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Scheme 2. Structures of the symmetric digalactosides with S/Se-glycosidic linkages. 













































a)  (H2N)2CSe, acetone, 60
oC, 1 h; b) Et3N, CH3CN, reflux, 1 h; c) NaOCH3, methanol, r.t., 10 min,  d) acetone, 
KOH, r.t., 30 min . 
Scheme 3. Synthetic pathway to compounds SeDG/DSeDG starting from the -bromo derivative of 
per-O-acetylated D-galactose. 
These two selenides were then introduced to both types of binding assays. The plant toxin was very 
reactive in the solid-phase assay (Table 1), in cell assays with different lines with similar grading 
(Fig. 2A, B). The human galectins also bound the selenodigalactoside (SeDG), with IC50-values 
comparable to TDG (Table 1). Cell assays confirmed a slightly better inhibitory potency than Lac for 
Gal-3 and -9N (Fig. 2C, D) and clearly stronger activity than Lac for Gal-4 (Fig. 3). Thus, bridging 
of two Gal residues by a Se-glycosidic bond yields a bioactive compound. Following the recent 
report that a methylseleno-substituted Lac derivative (at the Glc moiety) could be crystallized in 
complex with Gal-9N so that its structure could be obtained at the resolution of 1.4 Å,17 and the 
demonstration that the -methyl derivative of N-acetylglucosamine proved bioactive to form a 
6 
 
complex in crystals with a bacterial adhesin,
18
 our data now prove biocompatible Se-incorporation at 
sites of the ligand, which are in contact with the human bioeffectors. Seleno-carbohydrates, an area 
of synthesis started in 1921,
19
 can thus be designed for testing suitability for biomedical and 
analytical purposes. This experimental demonstration, solidifying previous indications for several 
classes of lectin by modeling,
10b
 encourages systematic structure-activity exploration for human 
galectins. Due to availability of full NMR assignments
20







H HSQC mapping, is a sensitive tool to detect ligand-specific structural changes, as 
done for Gal-1 and -galactosides.21 In view of our introduction of 19F-bearing carbohydrate ligands 
into the monitoring of lectin binding by NMR spectroscopy
22
 similar (or even combined) 
exploitation of sensor activity is envisioned for 
77
Se and human lectins. 
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IC50-values of S/Se-glycosides and free mono- and disaccharides in assays to block binding of 














1 0.75 (1.2/0.8) > 5 (n.i./<0.3) > 5 (n.i./<0.7) > 5 (n.i./<0.2) > 5 (n.i./<0.2) 
2 0.11 (8.2/5.5) > 5 (n.i./<0.3) > 5 (n.i./<0.7) > 5 (n.i./<0.2) > 5 (n.i./<0.2) 
3 0.06 (15/10) 3.2 (>1.6/0.5) 4.8 (>2.1/0.7) > 5 (n.i./<0.2)  4 (0.8/0.3) 
SeDG 0.25 (3.6/2.4) 1.4 (>3.6/1.1) 1.5  (>6.7/2.3) n. d. 0.8 (4.0/1.3) 
TDG
a
 0.4  (2.3/1.5) 1.1 (>4.5/1.5) 1.8  (>5.6/1.9) 1.4 (7.1/0.9) 0.8 (4.0/1.3)  
DSeDG 0.34 (2.6/1.8) 3.8 (>1.3/0.4) > 5  (n.i./<0.7) n. d. 2.8 (1.1/0.4) 
DTDG
a
 1.1  (0.8/ 0.5) 5.4 (>0.9/0.3) > 10 (n.i./<0.4) > 10 (n.i./<0.1) 2.6 (1.2/0.4) 
Gal 0.9   > 5  > 10  > 10  3.2  
Lac 0.6   1.6  3.5  1.2  1.0  
 
a
 from ref. 9c; titrations were performed in microtiter plate wells using constant concentrations of 
neoglycoprotein (lactosylated bovine serum albumin; 0.25 µg/well) for coating and of lectin as well 
as eight concentrations of sugar in triplicates and up to six independent series, reaching an upper 
limit of 14.6 % for the standard deviation; n. d.: not determined, n.i: not inhibitory. Number in 






Figure 1. Fluorescent surface staining (percentage of positive cells/mean fluorescence 
intensity) of human colon adenocarcinoma cells (SW480) by labeled VAA and its decrease 
by presence of test compounds. Staining profiles obtained with a lectin concentration of 2 
µg/ml in the absence of inhibitor (100%-value, bold number) and (listed from bottom to top) 
in the presence of 2 mM Gal, DTDG, compound 1 and compound 2 (A) or 2 mM Lac and 
compound 3 (B). The gray area defines lectin-independent staining (0%-value), its 







Figure 2. Fluorescent cell surface staining by labeled VAA (A, B), Gal-3 (C) and Gal-9N (D) 
of human B-lymphoblastoid (Croco II; A) and colon adenocarcinoma cells (SW480, B-D). 
Staining profiles obtained with a VAA concentration of 1 µg/ml in the absence of inhibitor 
and in the presence of 2 mM Lac, compound DSeDG and compound SeDG (A), with a VAA 
concentration of 2 µg/ml in the absence of inhibitor and 1 mM Lac, compound DSeDG and 
compound SeDG (B), with a Gal-3 concentration of 5 µg/ml in the absence of inhibitor and 
in the presence of 1 mM compound DSeDG, Lac and compound SeDG (C) and with a Gal-
9N concentration of 2 µg/ml in the absence of inhibitor and 5 mM compound DSeDG, Lac 





Figure 3. Fluorescent cell surface staining by labeled Gal-4 of human pancreatic 
adenocarcinoma cells (Capan-1) reconstituted for expression of the tumor suppressor p16
INK4a
 
by labeled Gal-4 (20 µg/ml). Test compounds (DSeDG, Lac and SeDG) were used at the 
concentration of 5 mM. 
 
